Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-11050 in HIV-Infected Adults on ART
NCT02652546Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing CC-11050 with Placebo (2 arms). Primary endpoint: Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) at 12 weeks. Started Jan 2016; status: completed.
02
Drugs
dovramilast
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02652546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02652546.